Sustained Smoking Cessation Support Improved Quit Rates After Psychiatric Discharge
Smoking remains deeply entrenched among adults with serious mental illness, and inpatient psychiatric care creates a narrow but meaningful opening for intervention. The Helping HAND 3 randomized clinical trial tested whether a multicomponent, sustained care strategy could turn that hospital stay into a bridge toward quitting rather than another missed opportunity. In a single-hospital study in Austin, Texas, adults who smoked daily and were receiving inpatient psychiatric care were randomized to either the sustained care program or usual care.
The intervention was built around a simple clinical idea with practical consequences: patients often leave psychiatric hospitalization with unresolved nicotine dependence, limited follow-up, and too little support to carry a quit attempt beyond discharge. A program that starts during admission and continues after discharge may close that gap. The trial’s design reflected that logic by combining inpatient motivational counseling, free transdermal nicotine patches at discharge, active offers of telephone quitline, text-based, and web-based counseling, and automated postdischarge voice or text prompts.
One result stood out immediately: the intervention arm quit more often.
Abstinence Gains Emerged at Six Months
The primary endpoint was biochemically verified 7-day point-prevalence abstinence at 6 months, a measure that is more stringent than self-report alone and clinically more credible in a population where relapse risk is high. Among 342 participants included in the analysis, the sustained care group achieved abstinence in 8.9% of cases compared with 3.5% in usual care. The adjusted odds ratio was 2.95 with a 95% confidence interval of 1.24 to 6.99, and the P value was .01.
The absolute quit rate remained modest, which is unsurprising in a cohort with chronic tobacco exposure and severe psychiatric illness. Even so, the relative difference matters because it shows that a structured discharge-linked model can move a hard endpoint, not just a process measure. The number needed to treat was 18.5, with a wide confidence interval from 9.6 to 306.4, reflecting both the low event rate and the uncertainty that comes with a modest absolute difference. In a setting where routine smoking cessation advice often fails to translate into sustained action, even a small absolute gain can represent meaningful clinical benefit across a large inpatient population.
The biological rationale is straightforward. Nicotine withdrawal, fragmented outpatient follow-up, and the behavioral weight of psychiatric symptoms all conspire against cessation after discharge. By pairing nicotine replacement with repeated contact and easy access to counseling, the program reduces withdrawal burden and reinforces treatment engagement during the period when relapse risk is highest.
Treatment Engagement Rose Sharply After Discharge
The secondary outcome may be even more important for real-world implementation: participants assigned to sustained care were far more likely to use smoking cessation treatment over the 6 months after discharge. Treatment use reached 74.6% in the intervention group versus 40.5% in usual care, with a relative risk of 1.8 and a 95% confidence interval of 1.51 to 2.25; P was less than .001.
This jump in treatment use suggests that the intervention did more than offer information. It created a pathway for follow-through. For individuals leaving psychiatric hospitalization, the challenge is not simply deciding to quit. It is accessing the next step, remembering it, tolerating the early withdrawal period, and persisting long enough for treatment to work. The combination of free nicotine patches, active referrals to quitline and digital counseling, and repeated automated outreach likely lowered the logistical friction that commonly prevents postdischarge engagement.
The study population helps frame the significance of the findings. Mean age was 35.8 years, and participants smoked an average of 16.9 cigarettes per day. The cohort was 78.4% White, 81.9% non-Hispanic, and 49.4% women. Those characteristics do not diminish the result, but they do define the population in which the intervention has already been tested. The setting was also highly specific: one hospital in Austin, Texas, over a four-year enrollment period from July 2015 through August 2019.
Why Psychiatric Hospitalization May Be the Right Entry Point
Hospital admission for psychiatric illness often concentrates risk and readiness in the same moment. Patients are in a supervised environment, they are already interacting with clinicians, and many are temporarily removed from their usual smoking cues. That combination gives inpatient teams a chance to initiate treatment before discharge, when the demands of daily life can overwhelm intent. A brief bedside conversation alone rarely survives the transition home. Sustained care is built to survive that transition with it.
The trial’s structure also reflects a broader truth about tobacco dependence in serious mental illness: advice is not enough when dependence is reinforced by routine, stress regulation, and comorbid psychiatric symptoms. Nicotine replacement can blunt withdrawal, but continued contact appears to matter just as much. The intervention’s automated messages and calls are not merely reminders; they function as repeated prompts to re-engage with a behavior change process that is often derailed in the first days after hospitalization.
A scalable model matters because most psychiatric inpatient units cannot deliver prolonged face-to-face cessation counseling after discharge. The use of free patches and remotely delivered counseling modalities makes the intervention more feasible than intensive in-person follow-up alone. Even in a single-center trial, the design points toward a workflow that hospitals could adapt without building an entirely new outpatient infrastructure.
What the Trial Shows and What It Does Not
Helping HAND 3 provides direct evidence that a multicomponent sustained care program can increase both smoking cessation treatment use and biochemically verified abstinence in adults with serious mental illness after psychiatric discharge. The intervention effect was statistically significant, and sensitivity analyses supported the main finding.
The trial does not erase the magnitude of the clinical problem. Most participants still did not achieve abstinence at 6 months, and the confidence interval around the number needed to treat was wide. The study was also conducted at a single site, which limits immediate generalizability to other psychiatric hospitals, other health systems, and populations with different demographic profiles or discharge resources. Still, the data make a clear case that psychiatric hospitalization can be used as a practical launch point for tobacco treatment rather than a pause in care.
For clinicians caring for patients with serious mental illness, the message is direct: discharge planning for tobacco dependence should not end with advice and a pamphlet. In this trial, sustained contact, nicotine replacement, and easy access to counseling produced more quit attempts that persisted into measurable abstinence at 6 months. The results identify a workable route for psychiatric units that want to treat smoking as part of the same continuum of care as the underlying mental illness.